Gut Microbiota Can Impact Chronic Murine Lung Allograft Rejection.

The role of the microbiome in regulation of immune homeostasis is well established, and its alteration underlies the immunopathogenesis of a variety of diseases (1, 2). Clinical and animal studies have recently found that derangement in the microbiome may impact transplant outcomes by contributing to allograft dysfunction after liver, small bowel, and skin transplantation (3–5). Clinical studies have also shown that lung transplantation alters the composition of the lung microbiome (6, 7). However, whether the gut microbiome can modulate lung transplant outcomes remains unknown. Lung allografts are limited by the development of chronic lung allograft rejection (8), and transplant-associated ischemia–reperfusion injury is a major risk factor for chronic lung allograft rejection (9–11). A recent animal study showed that administration of broadspectrum antibiotics to reduce gut microbiota can ameliorate lung ischemia–reperfusion injury (12). In a previous report, we found that CD4 T lymphocytes were required for the expansion of an IL-17A response in the lung allograft that is necessary for the development of obliterative bronchiolitis, the histological correlate of chronic lung allograft rejection (13). Gut microbiota can regulate T-helper cell type 17 (Th17) cell homeostasis (14), raising the possibility that alterations in the gut microbiota can impact lung allograft rejection. Hence, we hypothesized that alterations in microbiota may also impact lung transplant outcomes, particularly chronic lung allograft rejection, which is characterized by airway remodeling and fibrosis. To address this question, we used a minor mismatch model of orthotopic lung transplantation with C57BL/10 mice as donors and C57BL/6N mice as recipients in a pathogen-free facility, as we previously described (13). To alter the microbiota at the time of transplantation, both donor and recipient mice were treated by daily oral gavage (200 ml) with a cocktail of broad-spectrum antibiotics we previously reported (5), including gentamycin (0.35 mg/ml), kanamycin (5.25 mg/ml), colistin (8,500 U), metronidazole (2.15 mg/ml), and vancomycin (0.5 mg/ml) diluted in autoclaved water, starting 10 days before transplantation and ending the day before transplantation. In the control group, mice were treated with 200 ml of autoclaved water orally. This treatment timing was intended to reduce microbial diversity at the priming phase of the alloresponse, when T cells first encounter donor antigens, so that we could investigate whether dysbiosis at the priming stage affected Th17 differentiation after lung transplantation. We also hypothesized that the microbiota from not only the recipient but also the donor would modulate the alloresponse after lung transplantation. Therefore, we treated both donor and recipient mice with antibiotics. In the context of skin grafts, we previously showed that pretreatment of both donor and recipient mice with antibiotics prolonged graft survival, but pretreatment of only the donor or only the recipient did not alter graft outcomes (5). Moreover, continuing antibiotics after transplantation did not further prolong skin graft survival (M.-L.A., unpublished results). On Day 21 after transplantation, antibiotic pretreatment was associated with a decrease in the severity of rejection, as determined using established criteria (Figure 1). Five of the six mice pretreated with antibiotics developed only mild acute rejection, whereas the majority of control allografts developed moderate or severe acute rejection. In addition, allografts from antibiotic-pretreated mice developed less lung fibrosis compared with control mice (Figure 1; Table E1 in the data supplement). Remarkably, allografts from mice pretreated with the antibiotic regimen did not exhibit obliterative bronchiolitis injury, in contrast to the control mice. These data suggest that antibiotic pretreatment can ameliorate cellular rejection and obliterative airway fibrosis. To further determine whether antibiotic pretreatment in our animal model led to changes in the gut microbiome, we analyzed the composition of the fecal microbiota. We found that C57BL/6N and C57BL/10 fecal pellets had similar relative abundances of phyla under physiological conditions (Figure 2A). On Days 0 and 21 after transplantation, however, the antibiotic pretreatment regimen significantly increased Bacteroidetes and decreased Firmicutes (Figure 2B). We also identified 11 species (10 Clostridial species and Bacteroides dorei) whose variance was significantly better predicted by treatment and treatment interaction with time compared with time alone (Table E2). Importantly, the abundance of B. dorei was negatively correlated with allograft rejection and fibrosis, whereas several Clostridial species showed a positive correlation (Figure 2C). Prior studies have established a causal link between CD4 T effector lymphocytes and chronic lung allograft rejection in the murine model of lung transplantation (13). We have also found that depletion of CD4 T lymphocytes abrogates the IL-17 response in the minor–major histocompatibility complex mismatch model (13). Hence, we further analyzed T-cell subsets and IL-17 expression to determine whether the protection in lung allograft rejection associated with antibiotic pretreatment was due to a reduction in the IL-17 response. We did not find any changes in either the cellular composition or the absolute number of lymphocytes in the allografts (Figure E1). Specifically, there was no difference in T-cell subpopulations (CD4CD25Foxp3 regulatory T cells [Tregs] and IL17–producing T cells) between the treatment and control groups (Figure E1). Our data suggest that changes in the microbiota associated with reduced lung allograft pathology do not occur via impaired Th17 responses. Instead, the mechanism may be similar to that by which antibiotic pretreatment results in prolonged skin graft survival, namely, a decreased basal state in dendritic cell activation associated with diminished proliferation of graft-reactive T cells (5). Prior studies have demonstrated that metabolism of short-chain fatty Supported by grants from the National Institutes of Health (HL125940), the Thoracic Surgery Foundation, the American Lung Association, and the Society of University Surgeons (A.B.), and National Institutes of Health grant R01 HL109310 (R.S.).